The DOI matches its Crossref record.
Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates
Abstract
Nucleoside reverse-transcriptase inhibitors (NRTIs) are important components of most antiretroviral combination treatment regimens. Using a large collection of clinical isolates, we characterized patterns of cross-resistance among all NRTIs. Drugs were grouped by the effect of the M184V mutation: susceptibility to group 1 drugs (zidovudine, stavudine, tenofovir, and adefovir) increased when M184V was present, whereas susceptibility to group 2 drugs (didanosine, zalcitabine, abacavir, and lamivudine) decreased. Significant cross-resistance was observed among all NRTIs and was most notable when samples with or without M184V were analyzed separately. An increasing number of thymidine-analogue mutations (TAMs) was associated with a progressive reduction in drug susceptibility for all NRTIs. The modulating effect of M184I/V on drug susceptibility was present regardless of the number of TAMs. The broad range of susceptibility observed for viruses containing the same number of TAMs indicates that the genetic correlates of NRTI resistance remain to be fully elucidated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
2015 update of the drug resistance mutations in HIV-1
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Jacobsen, D. M., Paredes, R., Shafer, R. W., & Richman, D. D. (2015) · PubMed · doi:10.5167/uzh-122257 · Cited by 415
HIV-1 drug resistance and resistance testing
Clutter, D. S., Jordan, M. R., Bertagnolio, S., & Shafer, R. W. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.08.031 · Cited by 333
Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
Sax, P. E., Tierney, C., Collier, A. C., Fischl, M. A., Mollan, K., Peeples, L., Godfrey, C., Jahed, N. C., Myers, L., Katzenstein, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906768 · Cited by 313
Avoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106
Byun, H., Papathanasopoulos, M. A., Steegen, K., & Basson, A. E. (2024) · Viruses · doi:10.3390/v16121888 · Cited by 5
Metadata
- Authors
- Whitcomb, J. M., Parkin, N. T., Chappey, C., Hellmann, N. S., & Petropoulos, C. J.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-10
- Volume
- 188
- Issue
- 7
- Pages
- 992-1000
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2135450624
- Cited by
- 216
- References
- 0
- FWCI
- 10.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates. https://app.cochat.ai/papers/10.1086/378281
- The paper
- Whitcomb, J. M., Parkin, N. T., Chappey, C., Hellmann, N. S., & Petropoulos, C. J. (2003). Broad Nucleoside Reverse‐Transcriptase Inhibitor Cross‐Resistance in Human Immunodeficiency Virus Type 1 Clinical Isolates. The Journal of Infectious Diseases. https://doi.org/10.1086/378281
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.